BHC vs. TEVA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BHC and TEVA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BHC is a standard domestic listing, while TEVA trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | BHC | TEVA |
|---|---|---|
| Company Name | Bausch Health Companies Inc. | Teva Pharmaceutical Industries Limited |
| Country | Canada | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 2.81 billion USD | 20.92 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 29, 1994 | February 16, 1982 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of BHC and TEVA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BHC | TEVA |
|---|---|---|
| 5-Day Price Return | 9.32% | 1.08% |
| 13-Week Price Return | 65.24% | 0.07% |
| 26-Week Price Return | 18.96% | 1.60% |
| 52-Week Price Return | 37.80% | -11.57% |
| Month-to-Date Return | 32.07% | 6.92% |
| Year-to-Date Return | -7.14% | -26.16% |
| 10-Day Avg. Volume | 0.74M | 2.65M |
| 3-Month Avg. Volume | 0.45M | 2.25M |
| 3-Month Volatility | 60.52% | 23.35% |
| Beta | 1.33 | -0.27 |
Profitability
Return on Equity (TTM)
BHC
-96.76%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
BHC has a negative Return on Equity of -96.76%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
TEVA
-2.58%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
TEVA has a negative Return on Equity of -2.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
BHC
0.99%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Falling into the lower quartile for the Pharmaceuticals industry, BHC’s Net Profit Margin of 0.99% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
TEVA
-0.95%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
TEVA has a negative Net Profit Margin of -0.95%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
BHC
18.00%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
BHC’s Operating Profit Margin of 18.00% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
TEVA
5.38%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
TEVA’s Operating Profit Margin of 5.38% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | BHC | TEVA |
|---|---|---|
| Return on Equity (TTM) | -96.76% | -2.58% |
| Return on Assets (TTM) | 0.37% | -0.40% |
| Net Profit Margin (TTM) | 0.99% | -0.95% |
| Operating Profit Margin (TTM) | 18.00% | 5.38% |
| Gross Profit Margin (TTM) | 70.70% | 50.88% |
Financial Strength
Current Ratio (MRQ)
BHC
1.31
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
BHC’s Current Ratio of 1.31 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
TEVA
1.06
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
TEVA’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BHC
44.72
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
With a Debt-to-Equity Ratio of 44.72, BHC operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
TEVA
2.52
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.52, TEVA operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
BHC
1.12
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, BHC’s Interest Coverage Ratio of 1.12 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
TEVA
-0.38
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
TEVA has a negative Interest Coverage Ratio of -0.38. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | BHC | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 1.31 | 1.06 |
| Quick Ratio (MRQ) | 0.79 | 0.68 |
| Debt-to-Equity Ratio (MRQ) | 44.72 | 2.52 |
| Interest Coverage Ratio (TTM) | 1.12 | -0.38 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BHC
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
BHC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
TEVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BHC
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
BHC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
TEVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BHC | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BHC
29.35
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
A P/E Ratio of 29.35 places BHC in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
TEVA
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for TEVA is currently unavailable.
Price-to-Sales Ratio (TTM)
BHC
0.29
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, BHC’s P/S Ratio of 0.29 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
TEVA
1.25
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, TEVA’s P/S Ratio of 1.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BHC
12.64
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 12.64, BHC’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
TEVA
2.80
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
TEVA’s P/B Ratio of 2.80 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BHC | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 29.35 | -- |
| Price-to-Sales Ratio (TTM) | 0.29 | 1.25 |
| Price-to-Book Ratio (MRQ) | 12.64 | 2.80 |
| Price-to-Free Cash Flow Ratio (TTM) | 2.61 | 18.48 |